Polysorbate 20 (PS20) is one of the most commonly used non-ionic surfactants in cosmetics, pharmaceuticals and food products. Considered as biocompatible and non-irritating, it is further valued for its solubilising and protein stabilising properties. PS20 is manufactured through a multi-stage reaction of sorbitol with various fatty acids and ethylene oxide, resulting in a complex mixture of components with different molecular weights and polarity. Since variations in the distribution of these components can influence its performance, such as the emulsifying or solubilising efficiency, a detailed understanding of the PS20 composition is of importance. Herein we introduce a combined approach of reversed-phase chromatography with mass detection and automated stochastic modelling that enables the quantitative characterisation of PS20 at the component level. With two straightforward sample preparations and two methods for an ultra-high performance liquid chromatography (UPLC) system coupled to a single quadrupole mass (QDa) detector, this technique ensures efficient data acquisition. Seven PS20 products of different manufacturers, age and qualities were studied using the presented approach. Molar contents and weight percentages were calculated for each of the more than 27'700 components of the PS20, which were fully characterised by i) the substance class (i.e. sorbitan, isosorbide or polyoxyethylene (POE)), ii) the number of esters, iii) the fatty acid combination and iv) the number of OE units. The obtained results allowed not only an accurate prediction of bulk parameters, such as hydroxyl and saponification values, but also a detailed product comparison.
The stratum corneum (SC) lipids provide the main barrier of the skin against the environment. Ceramides make up about half of the lipids by weight and are thus of particular interest. Emulsifiers are used in a multitude of topical formulations, e.g., to stabilize emulsions against coalescence. Investigations showed that some emulsifiers have the potential to impair skin barrier function. Sorbitan esters (SEs) are frequently used emulsifiers in pharmaceutical and cosmetic dermal formulations. Further, cholesterol and lecithin were used as natural alternatives. However, information on their impact on ceramides is very scarce. Thus, we first analyzed the SEs by LC-MS with regard to their composition. Then we developed an LC-MS method to identify and quantify the ceramides in porcine skin and subsequently investigated the impact of emulsifiers on the ceramide profile. Besides the LC-MS measurements, the effect of emulsifiers on the skin barrier function was investigated by trans-epidermal water loss (TEWL) measurements and confocal Raman spectroscopy (CRS). Throughout the experiments, water was used as a negative control and sodium lauryl sulfate (SLS) as a positive control. It was found that SEs are mixtures of mono-, di-, and triesters, partially with a complex fatty acid distribution. LC-MS measurements of the total ceramide content of the SC samples revealed the SE 60 and cholesterol-treated samples to be those showing the least ceramide depletion, implying a high skin tolerability in general. The TEWL measurements showed that SEs 40, 60, 80, and 120 showed no significant changes in skin barrier function. The lipid content, measured by CRS, was mostly decreased except for SE 120. Conformation, chain order, and SC thickness, also measured by CRS, showed no significant differences. These detailed investigations lead to the view that SEs are skin-friendly substances and can be used for topical applications, e.g., those commonly used to treat skin diseases.
Specific aspects of semi-solid dosage forms for topical application include the nature of the barrier to be overcome, aspects of susceptibility to physical and chemical instability, and a greater influence of sensory perception. Advances in understanding the driving forces of skin penetration as well as the design principles and inner structure of formulations, provide a good basis for the more rational design of such dosage forms, which still often follow more traditional design approaches. This review analyses the opportunities and constraints of rational formulation design approaches in the industrial development of new topical drugs. As the selection of drug candidates with favorable physicochemical properties increases the speed and probability of success, models for drug selection based on theoretical and experimental approaches are discussed. This paper reviews how progress in the scientific understanding of mechanisms and vehicle-influence of skin penetration can be used for rational formulation design. The characterization of semi-solid formulations is discussed with a special focus on modern rheological approaches and analytical methods for investigating and optimizing the chemical stability of active ingredients in consideration of applicable guidelines. In conclusion, the combination of a good understanding of scientific principles combined with early consideration of regulatory requirements for product quality are enablers for the successful development of innovative and robust semi-solid formulations for topical application.
Polysorbates are widely used as non-ionic surfactant in biopharmaceutical formulations. Recently, the degradation of polysorbate moved into the focus of attention, because in several published studies it was described, that stability issues in polysorbate containing formulations were observed leading to the formation and appearance of sub-visible and visible particles. For this reason, monitoring of polysorbate and its degradation products is of importance throughout the development of parenterals. The aim of the study was to develop a method for the selective marker-based quantification of adequate polysorbate 20 components of interest without the need to apply derivatization or complex detection techniques. A single quadrupole mass (QDa) detector was used coupled to an ultra-high performance liquid chromatography (UPLC) system. Method development was based on a reversed phase-high performance liquid chromatography assay coupled to a charged aerosol detector (RP-HPLC CAD). Instead of a charged aerosol detector (CAD) a QDa detector was used in order to significantly improve the selectivity. The focus of this study is the development of the QDa based method for the analysis of polysorbate 20. Modifications of the mobile phase and the type of chromatography column allowed the separation of several components of polysorbate 20 from polar non-esterified to apolar higher order species. In addition, a multitude of components could be quantified by their individual m/z values. The peak assignment identified 676 compounds which originated from polysorbate 20. Some of these were selected and defined as marker components. It was shown that the developed method is capable to determine polysorbate 20 in different biopharmaceutical formulations. The proposed assay is based on a smart sample preparation as well as a unique calibration procedure that make the determination of several selected components achievable. Furthermore, it was successfully demonstrated that the analytical procedure is valid to reliably quantify several polysorbate 20 components at its 100% level (corresponds to 0.4 mg/mL intact polysorbate 20) and even at lower concentrations that occur e.g. in case of polysorbate 20 degradation. In conclusion, the method is beneficial to determine selected polysorbate 20 species during formulation development of biopharmaceuticals as well as during stability testing and trouble shooting.
The Skin Parallel Artificial Membrane Permeability Assay (PAMPA) is a 96-well plate–based skin model with an artificial membrane containing free fatty acid, cholesterol, and synthetic ceramide analogs to mimic the stratum corneum (SC) barrier. The current study evaluates the compatibility of lipophilic solvents/penetration enhancer, topical emulsions containing different emulsifier systems, and organic acceptor media additives with the artificial membrane of the assay. Additionally, different assay setups (standard setup: donor in bottom plate versus modified setup: donor in top plate) were compared. Methylparaben (MP), ethylparaben (EP), and propylparaben (PP) were used as model permeants and internal standards for proper assay execution. The permeation order of the parabens (MP > EP > PP) remained the same with different lipophilic solvents, and the ranking of lipophilic solvents was comparable under standard and modified conditions (isopropyl myristate, IPM > dimethyl isosorbide, DMI ≥ propylene glycol, PG > diisopropyl adipate, DIPA). Pre-incubation of the Skin PAMPA plates with IPM, DIPA, and DMI, as well as with formulations that contain non-ionic emulsifiers, and acceptor solutions containing DMSO or EtOH (≤ 50%) for 4 h did not increase the percentage of permeated parabens in the main experiment, suggesting that those compounds do not make the artificial membrane more permeable. High-resolution mass spectrometry confirmed that acceptor solutions with ≤ 50% DMSO or EtOH do not extract stearic acid, cholesterol, and certramides at standard assay conditions. Hence, if certain constraints are considered, the Skin PAMPA model can be used as a pre-screening tool for topical formulation selection.
Solubilization of drugs in aqueous phases of liquid and semisolid environment is typically achieved by co-solvents or surfactants. On contrast, solubilization by means of hydrotropic agents, i.e., small hydrophilic organic compounds like urea or citric acid, is little explored in the context of pharmaceutical formulations. Especially, with regard to topical dosage forms, however, hydrotropic solubilization can provide valuable alternatives to establish solubilization approaches. A difficulty of employing hydrotropic solubilization was that its extent could not be predicted for different drug molecules. Using a chemically heterogeneous set of 12 compounds relevant for dermatology (with overall 16 different log D values tested), we were able to demonstrate that hydrotropic effects of urea can be predicted by log D values of drugs. All compounds with log D values between 2 and 4.5 showed a solubility enhancement factor (EF) of >5 in 40% aqueous solutions of urea. For log D values below 2 or above 5, only EF < 5 were found. For some compounds, e.g., diclofenac (pH 4) and prednicarbate could achieved only EF > 5 at 5% urea and EF > 250 at 20% urea.